{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:21:43Z","timestamp":1790256103981,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008661","name":"MIKIYA Science and Technology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008668","name":"Shorai Foundation for Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008965","name":"Takahashi Industrial and Economic Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008965","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K11151"],"award-info":[{"award-number":["17K11151"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["26460149"],"award-info":[{"award-number":["26460149"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.cbi.2023.110840","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T23:54:21Z","timestamp":1702943661000},"page":"110840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine\/cisplatin resistance in bladder cancer"],"prefix":"10.1016","volume":"388","author":[{"given":"Rin","family":"Himura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsumi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0578-9672","authenticated-orcid":false,"given":"Satoshi","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2023.110840_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.cbi.2023.110840_bib2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.cbi.2023.110840_bib3","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eururo.2013.11.046","article-title":"EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines","volume":"65","author":"Witjes","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.cbi.2023.110840_bib4","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.eururo.2011.03.023","article-title":"Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines","volume":"59","author":"Stenzl","year":"2011","journal-title":"Eur. Urol."},{"key":"10.1016\/j.cbi.2023.110840_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.mce.2017.06.021","article-title":"Role of the androgen receptor in urothelial cancer","volume":"465","author":"Inoue","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.cbi.2023.110840_bib6","first-page":"10","article-title":"Sex hormone receptor signaling in bladder cancer: a potential target for enhancing the efficacy of conventional non-surgical therapy","author":"Ide","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.cbi.2023.110840_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/14656566.9.2.211","article-title":"Androgen deprivation therapy for prostate cancer","volume":"9","author":"Singer","year":"2008","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.cbi.2023.110840_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174746","article-title":"Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: a meta-analysis of immunohistochemical studies","volume":"12","author":"Ide","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cbi.2023.110840_bib9","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.21037\/tcr.2020.01.06","article-title":"The prognostic role of steroid hormone receptor signaling pathways in urothelial carcinoma","volume":"9","author":"Nagata","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.cbi.2023.110840_bib10","doi-asserted-by":"crossref","first-page":"49169","DOI":"10.18632\/oncotarget.9994","article-title":"Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer","volume":"7","author":"Kashiwagi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cbi.2023.110840_bib11","first-page":"3111","article-title":"Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer","volume":"41","author":"Sekino","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cbi.2023.110840_bib12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.urolonc.2019.03.008","article-title":"Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder","volume":"37","author":"Tyagi","year":"2019","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.cbi.2023.110840_bib13","doi-asserted-by":"crossref","first-page":"10396","DOI":"10.1021\/acs.jmedchem.0c00939","article-title":"Development of novel AKR1C3 inhibitors as new potential treatment for castration-resistant prostate cancer","volume":"63","author":"Endo","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2023.110840_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.cbi.2008.10.024","article-title":"Type 5 17beta-hydroxysteroid dehydrogenase\/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs","volume":"178","author":"Byrns","year":"2009","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cbi.2023.110840_bib15","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-09-3237","article-title":"The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3","volume":"70","author":"Guise","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2023.110840_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2011.02.027","article-title":"PTHrP stimulates prostate cancer cell growth and upregulates aldo-keto reductase 1C3","volume":"306","author":"Downs","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cbi.2023.110840_bib17","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1021\/np201002x","article-title":"Selective inhibition of human type-5 17beta-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis","volume":"75","author":"Endo","year":"2012","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.cbi.2023.110840_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MED.0b013e3283381a31","article-title":"New frontiers in androgen biosynthesis and metabolism","volume":"17","author":"Penning","year":"2010","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.cbi.2023.110840_bib19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/pros.10139","article-title":"Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues","volume":"53","author":"Koh","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.cbi.2023.110840_bib20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jsbmb.2013.05.012","article-title":"AKR1C3 as a target in castrate resistant prostate cancer","volume":"137","author":"Adeniji","year":"2013","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.cbi.2023.110840_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2020.105586","article-title":"Human dehydrogenase\/reductase SDR family member 11 (DHRS11) and aldo-keto reductase 1C isoforms in comparison: substrate and reaction specificity in the reduction of 11-keto-C(19)-steroids","volume":"199","author":"Endo","year":"2020","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.cbi.2023.110840_bib22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cbi.2010.12.017","article-title":"Roles of rat and human aldo-keto reductases in metabolism of farnesol and geranylgeraniol","volume":"191","author":"Endo","year":"2011","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cbi.2023.110840_bib23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cbi.2012.09.024","article-title":"Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers","volume":"202","author":"Matsunaga","year":"2013","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cbi.2023.110840_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/jb\/mvab025","article-title":"Targeting Nrf2-antioxidant signalling reverses acquired cabazitaxel resistance in prostate cancer cells","volume":"170","author":"Endo","year":"2021","journal-title":"J. Biochem."},{"key":"10.1016\/j.cbi.2023.110840_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2023.109519","article-title":"Artepillin C overcomes apalutamide resistance through blocking androgen signaling in prostate cancer cells","volume":"735","author":"Ota","year":"2023","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.cbi.2023.110840_bib26","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1021\/acs.jmedchem.1c02113","article-title":"Discovery and structure-based optimization of novel Atg4B inhibitors for the treatment of castration-resistant prostate cancer","volume":"65","author":"Kudo","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2023.110840_bib27","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1046\/j.1432-1327.2000.01606.x","article-title":"Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity","volume":"267","author":"O'Brien","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.cbi.2023.110840_bib28","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/j.1464-410X.2011.10706.x","article-title":"Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder","volume":"109","author":"Miyamoto","year":"2012","journal-title":"BJU Int."},{"key":"10.1016\/j.cbi.2023.110840_bib29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.cbi.2023.110840_bib30","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/jnci\/djk113","article-title":"Promotion of bladder cancer development and progression by androgen receptor signals","volume":"99","author":"Miyamoto","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.cbi.2023.110840_bib31","doi-asserted-by":"crossref","first-page":"29860","DOI":"10.18632\/oncotarget.5007","article-title":"ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression","volume":"6","author":"Kawahara","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.cbi.2023.110840_bib32","article-title":"Histone demethylase KDM7A regulates androgen receptor activity, and its chemical inhibitor TC-E 5002 overcomes cisplatin-resistance in bladder cancer cells","volume":"21","author":"Lee","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cbi.2023.110840_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120622","article-title":"A molecular analysis provides novel insights into androgen receptor signalling in breast cancer","volume":"10","author":"Mehta","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cbi.2023.110840_bib34","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cbi.2023.110840_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810030","article-title":"Androgen receptor signaling induces cisplatin resistance via down-regulating GULP1 expression in bladder cancer","volume":"22","author":"Teramoto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cbi.2023.110840_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13050975","article-title":"Identification of BXDC2 as a key downstream effector of the androgen receptor in modulating cisplatin sensitivity in bladder cancer","volume":"13","author":"Jiang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cbi.2023.110840_bib37","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1111\/cas.14557","article-title":"FOXO1 inactivation induces cisplatin resistance in bladder cancer","volume":"111","author":"Ide","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.cbi.2023.110840_bib38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.juro.2016.08.006","article-title":"Suppressed recurrent bladder cancer after androgen suppression with androgen deprivation therapy or 5alpha-reductase inhibitor","volume":"197","author":"Shiota","year":"2017","journal-title":"J. Urol."},{"key":"10.1016\/j.cbi.2023.110840_bib39","doi-asserted-by":"crossref","first-page":"50 e11","DOI":"10.1016\/j.urolonc.2022.09.004","article-title":"5alpha-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort","volume":"41","author":"Dekalo","year":"2023","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.cbi.2023.110840_bib40","first-page":"481","article-title":"5\u03b1-Reductase inhibitors do not prevent the development and progression of urothelial cancer: in vitro evidence bladder","volume":"6","author":"Nagata","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.cbi.2023.110840_bib41","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s10637-014-0130-5","article-title":"In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17beta-hydroxysteroid dehydrogenase type 5 (17betaHSD5; AKR1C3)","volume":"32","author":"Kikuchi","year":"2014","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.cbi.2023.110840_bib42","first-page":"578","article-title":"Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study","volume":"188","author":"Gashaw","year":"2023","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.cbi.2023.110840_bib43","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/carcin\/bgp176","article-title":"Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds","volume":"30","author":"MacLeod","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cbi.2023.110840_bib44","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.urolonc.2014.02.006","article-title":"The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer","volume":"32","author":"Hayden","year":"2014","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.cbi.2023.110840_bib45","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jb\/mvaa027","article-title":"JUND-dependent up-regulation of HMOX1 is associated with cisplatin resistance in muscle-invasive bladder cancer","volume":"168","author":"Peng","year":"2020","journal-title":"J. Biochem."},{"key":"10.1016\/j.cbi.2023.110840_bib46","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/carcin\/bgn163","article-title":"Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes","volume":"29","author":"Figueroa","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cbi.2023.110840_bib47","first-page":"2615","article-title":"Association of AKR1C3 polymorphisms with bladder cancer","volume":"13","author":"Tiryakioglu","year":"2016","journal-title":"Urol. J."},{"key":"10.1016\/j.cbi.2023.110840_bib48","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/0090-4295(94)90136-8","article-title":"DNA ploidy and P-glycoprotein expression as predictive factors of response to neoadjuvant chemotherapy for invasive bladder cancer","volume":"43","author":"Sandlow","year":"1994","journal-title":"Urology"},{"key":"10.1016\/j.cbi.2023.110840_bib49","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/bjc.1996.115","article-title":"Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder","volume":"73","author":"Clifford","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cbi.2023.110840_bib50","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1158\/1078-0432.CCR-04-0137","article-title":"Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells","volume":"10","author":"Samimi","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cbi.2023.110840_bib51","first-page":"1312","article-title":"Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance","volume":"60","author":"Komatsu","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2023.110840_bib52","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/annonc\/mdl435","article-title":"Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy","volume":"18","author":"Bellmunt","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cbi.2023.110840_bib53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12943-022-01517-9","article-title":"Targeting HNRNPU to overcome cisplatin resistance in bladder cancer","volume":"21","author":"Shi","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cbi.2023.110840_bib54","first-page":"1068","article-title":"The roles and mechanisms of YTH domain-containing proteins in cancer development and progression","volume":"10","author":"Liu","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.cbi.2023.110840_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13404","article-title":"YTHDC1 positively regulates PTEN expression and plays a critical role in cisplatin resistance of bladder cancer","volume":"56","author":"Su","year":"2023","journal-title":"Cell Prolif."},{"key":"10.1016\/j.cbi.2023.110840_bib56","article-title":"YTHDF1 promotes bladder cancer cell proliferation via the METTL3\/YTHDF1-RPN2-PI3K\/AKT\/mTOR Axis","volume":"24","author":"Zhu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cbi.2023.110840_bib57","first-page":"2523","article-title":"Estrogen receptor-beta signaling induces cisplatin resistance in bladder cancer","volume":"10","author":"Goto","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.cbi.2023.110840_bib58","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s12094-022-03044-x","article-title":"ADAM12 promotes gemcitabine resistance by activating EGFR signaling pathway and induces EMT in bladder cancer","volume":"25","author":"Wang","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.cbi.2023.110840_bib59","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.7150\/thno.19542","article-title":"TGFbeta1 promotes gemcitabine resistance through regulating the LncRNA-LET\/NF90\/miR-145 signaling Axis in bladder cancer","volume":"7","author":"Zhuang","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.cbi.2023.110840_bib60","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/CAD.0000000000000112","article-title":"Induction of aldo-keto reductases (AKR1C1 and AKR1C3) abolishes the efficacy of daunorubicin chemotherapy for leukemic U937 cells","volume":"25","author":"Matsunaga","year":"2014","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.cbi.2023.110840_bib61","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1158\/0008-5472.CAN-14-3080","article-title":"Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2023.110840_bib62","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.mce.2005.12.009","article-title":"Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors","volume":"248","author":"Penning","year":"2006","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.cbi.2023.110840_bib63","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3892\/or.2017.5480","article-title":"Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity","volume":"37","author":"Shiiba","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cbi.2023.110840_bib64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1535-7163.MCT-16-0186","article-title":"Inhibition of AKR1C3 activation overcomes resistance to abiraterone in advanced prostate cancer","volume":"16","author":"Liu","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.cbi.2023.110840_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2020.109295","article-title":"Significance of aldo-keto reductase 1C3 and ATP-binding cassette transporter B1 in gain of irinotecan resistance in colon cancer cells","volume":"332","author":"Matsunaga","year":"2020","journal-title":"Chem. Biol. Interact."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279723005070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279723005070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:52:15Z","timestamp":1736383935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279723005070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":65,"alternative-id":["S0009279723005070"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2023.110840","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine\/cisplatin resistance in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2023.110840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110840"}}